These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37228779)

  • 1. Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.
    Li R; Wang T; Lyv R; Wang Y; Yu Y; Yan Y; Sun Q; Xiong W; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
    Blood Sci; 2023 Apr; 5(2):118-124. PubMed ID: 37228779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
    Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].
    Wang N; Xu PP; Wang L; Cheng S; Zhao WL; Sun HP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):46-51. PubMed ID: 30704228
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
    Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova J; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2016 May; 57(5):1094-103. PubMed ID: 26293000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
    Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
    Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
    Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
    Hirt C; Hoster E; Unterhalt M; Hänel M; Prange-Krex G; Forstpointner R; Florschütz A; Graeven U; Frickhofen N; Wulf G; Lengfelder E; Lerchenmüller C; Schlag R; Dierlamm J; Fischer von Weikersthal L; Ahmed A; Harich HD; Rosenwald A; Klapper W; Dreyling M; Hiddemann W; Herold M
    Hemasphere; 2021 Jul; 5(7):e600. PubMed ID: 34179697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
    Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
    Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
    Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
    Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
    Xue LG; Shen HR; Gao R; Du KX; Xing TY; Wang WT; Wang L; Li JY; Liang JH; Xu W
    Ann Hematol; 2023 Apr; 102(4):851-862. PubMed ID: 36735075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End of induction [
    Guerra L; Chauvie S; Fallanca F; Bergesio F; Marcheselli L; Durmo R; Peano S; Franceschetto A; Monaco L; Barbieri E; Ladetto M; Musuraca G; Tosi P; Bianchi B; Bolis SAM; Pavone V; Chiarenza A; Arcari A; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Roti G; Galimberti S; Gini G; Falcinelli F; Vitolo U; Usai SV; Stefani PM; Ibatici A; Liberati AM; Pennese E; Perrone T; Versari A; Luminari S;
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3311-3321. PubMed ID: 38795120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
    Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
    Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
    Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
    Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.